Kazia Therapeutics (NASDAQ: KZIA) Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma
GBM AGILE trial data shows clinically meaningful improvement in a prespecified secondary analysis for overall survival in paxalisib-treated, newly diagnosed unmethylated patients with glioblastoma SYDNEY, July 10, 2024 — Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused […]